噻托溴铵与沐舒坦联合应用对AECOPD患者肺功能的保护作用
2017-10-17聂洪洲
聂洪洲
[摘要] 目的 观察噻托溴铵与沐舒坦联合应用对AECOPD患者肺功能的保护作用。 方法 共收集2015年1月~2016年10月期间我院收治的110例AECOPD患者作为研究对象,将110例患者按照治疗方法分为两组,研究组和对照组,每组各55例。两组患者给予常规治疗,包括吸氧、抗炎、补液、纠正电解质紊乱及维持酸碱平衡、给予止咳平喘药物及对症治疗,除此之外,研究组用噻托溴铵与沐舒坦联合治疗,比较两组临床疗效及治疗前后第1秒用力呼气容积(FEV1)、FEV1/1秒用力肺活量(FVC)。 结果 研究组总有效率为92.73%,对照组总有效率为76.36%,研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组和对照组FEV1、FEV1/FVC相较于治疗前明显升高,与治疗前比较差异有统计学意义(P<0.05);治疗后研究组FEV1、FEV1/FVC高于对照组,两组差异有统计学意义(P<0.05)。 结论 噻托溴铵与沐舒坦联合应用于AECOPD治疗中效果显著,可提高临床治疗总有效率,改善患者的肺功能,建议在临床推广应用。
[关键词] 慢性阻塞性肺疾病;噻托溴铵;沐舒坦;肺功能
[中图分类号] R563.9 [文献标识码] B [文章编号] 1673-9701(2017)24-0118-03
[Abstract] Objective To observe the protective effect of Levetiracetam combined with Mucosolvan on pulmonary function in patients with AECOPD. Methods A total of 110 patients with AECOPD admitted in our hospital from January 2015 to October 2016 were enrolled in this study. The 110 patients were divided into two groups according to the treatment methods, including the study group(n=55) and the control group(n=55). The two groups of patients were treated with conventional treatment, including oxygen, anti-inflammatory, fluid infusion, correcting electrolyte imbalance, maintaining acid-base balance, cough and asthma drugs and symptomatic treatment. In addition, the study group was given Levetiracetam combined with Mucosolvan treatment. The clinical efficacy, the first second forced expiratory volume (FEV1) and FEV1/1 second forced vital capacity(FVC) of the two groups before and after treatment were compared. Results The total effective rate was 92.73% in the study group and 76.36% in the control group. The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant(P<0.05). After treatment, FEV1 and FEV1/FVC in the study group and control group were significantly higher than those before treatment, with significant difference(P<0.05). After treatment, FEV1 and FEV1/FVC in the study group were higher than those in the control group. The differences between the two groups were statistically significant(P<0.05). Conclusion Levetiracetam combined with Mucosolvan used in the treatment of AECOPD has significant effect, which can improve the total effective rate of clinical treatment and improve the lung function of patients, and is recommended in the clinical application.
[Key words] Chronic obstructive pulmonary disease; Levetiracetam; Mucosolvan; Pulmonary function
慢性阻塞性肺疾病(COPD)是一種临床常见的慢性疾病,中老年人为COPD的好发人群,有较高的发病率及死亡率,不仅给患者的劳动能力及生活质量均造成严重的影响,还给社会、家庭带来沉重的经济负担[1]。慢性阻塞性肺疾病急性加重(AECOPD)为COPD患者在一些诱因的作用下诱发疾病急性发作,患者病情加重[2],有研究表明,AECOPD可诱发患者肺部通气功能损伤,加快病情进展,使患者身体康复速度及远期预后受到影响[3]。AECPOD治疗的关键为解除可逆部分的气流陷闭,改善通气。因此,如何选择有效的治疗药物对AECOPD患者临床症状的改善及死亡率的降低等均有重要的临床意义。本研究中共收集110例AECOPD患者作为研究对象,对其中的55例患者用噻托溴铵与沐舒坦联合治疗,以观察两种药物联合应用对AECOPD患者肺功能的保护作用,现报道如下。……
